Unsurprisingly, the horse dewormer Ivermection did not meaningfully improve recovery times for mild to moderate COVID-19 patients in a controlled clinical study published in the Journal of the American Medical Association.
Findings In this double-blinded, randomized, placebo-controlled platform trial conducted in the US during a period of Delta and Omicron variant predominance, and that included 1591 adult outpatients with COVID-19, the posterior probability of improvement in time to recovery in those treated with ivermectin vs placebo had a hazard ratio of 1.07, with a posterior probability of benefit of .91. This did not meet the prespecified threshold of posterior probability greater than .95.
Meaning These findings do not support the use of ivermectin in outpatients with mild to moderate COVID-19.
Reminder: The Food and Drug Administration has not authorized ivermectin for treating or preventing Covid and has repeatedly warned people against taking the drug for anything other than its approved purpose.